Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sheng, Xi'nan"'
Autor:
Zeng, Ziqing, Zheng, Yong, Yan, Xieqiao, Tao, Jinping, Li, Liqiang, Ding, Jin, Sheng, Xi’nan, Zhu, Hua, Yang, Zhi
Publikováno v:
In Biomedicine & Pharmacotherapy September 2024 178
Autor:
Ren, Ya'nan, Liu, Teli, Li, Siming, Ma, Xiaokun, Xia, Lei, Wang, Pei, Guo, Qian, Yao, Yuan, Hou, Xingguo, Sheng, Xi'nan, Zhu, Hua, Yang, Zhi
Publikováno v:
In International Journal of Pharmaceutics 15 February 2024 651
Autor:
ZHOU Li, SHENG Xi'nan
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 47, Iss 3, Pp 149-153 (2020)
Immunotherapy has made great progress in the treatment of advanced renal cell carcinoma (RCC), since nivolumab was approved for the second-line therapy of advanced RCC. The efficacy of antiPD1 monotherapy was limited in the first-line setting, theref
Externí odkaz:
https://doaj.org/article/984f42054c63455c94fee57f3d7f4bb2
Autor:
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 45, Iss 11, Pp 879-882 (2018)
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation. Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or muco
Externí odkaz:
https://doaj.org/article/68e3be16fdec4b8dbf3e2af696042491
Autor:
ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 45, Iss 6, Pp 400-403 (2018)
Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively. Methods Patients with intermediate- or poor-risk
Externí odkaz:
https://doaj.org/article/823b67113a5a472db5b22235f2ad3eb0